Mindpeak secures $15.3M in series A funding to accelerate growth in AI-based digital pathology Funding strengthens the product development roadmap for AI-powered histopathological assessments, supporting clinical labs and biopharma companies worldwide.

Unlocking the Future of Pathology with AI: Meet our Team at ECP 2024

Mindpeak unveiled a new product to empower pathologists in detecting and grading prostate cancer.

We are looking forward to meeting you in person, at USCAP 2024, Baltimore (MD), USA. Meet our CEO Felix Faber and our experts Patrick Frey and Timm Goempel at our booth (no 863).

A refined approach for AI-assisted cancer diagnosis was developed by setting standards in the interpretation of scoring guidelines with a "PD-L1 Cell Atlas".

In a study investigating the efficiency gain in clinical routine with our AI Unilabs reported saving up to 90% diagnostic time compared to manual scoring. In addition, several patients needed to be re-classified leading to the identification of more patients eligible for treatment in the prospective study setting.